BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company will host a conference call on March 27, 2025, to discuss its financial results for Q4 and the full year ended December 31, 2024 [1][2] Company Overview - BioAtla operates in San Diego, California, and has a partnership in Beijing, China for preclinical development services [3] - The company utilizes proprietary CAB technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - BioAtla holds over 780 active patent matters, with more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Clinical Development - BioAtla has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The company is also developing evalstotug, a CAB-CTLA-4 antibody designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors [3] - BA3182, the first dual CAB bispecific T-cell engager antibody, is currently in Phase 1 development, targeting EpCAM on adenocarcinomas [3]